<DOC>
	<DOCNO>NCT01282762</DOCNO>
	<brief_summary>The purpose study determine durability seroprotection HEPLISAV™ Engerix-B® number injection vaccine need maintain seroprotection cohort chronic kidney disease ( CKD ) patient time .</brief_summary>
	<brief_title>Long-Term Study Safety Immunogenicity HEPLISAV™ Engerix-B® Adults With Chronic Kidney Disease</brief_title>
	<detailed_description>An Observational Study Evaluating Long-Term Safety Immunogenicity HEPLISAV™ compare Engerix-B® Adults Chronic Kidney Disease Have Previously Received At Least One Hepatitis B Vaccine Series</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A subject must meet follow inclusion criterion participate study : enrol complete HEPLISAV EngerixB treatment : DV2HBV17 DV2HBV18 antiHBsAg ≥ 10 mIU/mL prior DV2HBV18 previously receive complete primary hepatitis B vaccine series DV2HBV17 prior enrollment DV2HBV18 otherwise clinically stable opinion investigator able willing provide inform consent A subject meet ONE follow exclusion criterion permit participate study : previously enrol DV2HBV18 never obtain antiHBsAg ≥ 10 mIU/mL receive hepatitis B vaccine offstudy enrol DV2HBV17 DV2HBV18 know history autoimmune disease unwilling unable comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prevention Hepatitis B infection .</keyword>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Hepatitis B vaccination</keyword>
	<keyword>Hepatitis B virus ( HBV )</keyword>
</DOC>